BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 34738855)

  • 61. Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy.
    Micov AM; Tomić MA; Todorović MB; Vuković MJ; Pecikoza UB; Jasnic NI; Djordjevic JD; Stepanović-Petrović RM
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Dec; 103():109975. PubMed ID: 32464241
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oxaliplatin-induced peripheral neuropathy risk factors and management in Tunisian population.
    Zribi A; Nasr SB; Hamdi S; Ayari J; Fendri S; Balti M; Haddaoui A
    Pan Afr Med J; 2020; 35():83. PubMed ID: 32537086
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
    Gao Y; Guo X; Han P; Li Q; Yang G; Qu S; Yue L; Wang CN; Skljarevski V; Dueñas H; Raskin J; Gu L
    Int J Clin Pract; 2015 Sep; 69(9):957-66. PubMed ID: 25939897
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
    Kerckhove N; Tougeron D; Lepage C; Pezet D; Le Malicot K; Pelkowski M; Pereira B; Balayssac D
    BMC Cancer; 2022 Jul; 22(1):742. PubMed ID: 35799138
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Lidocaine Infusion Versus Duloxetine for Prevention and Management of Taxane-Induced Peripheral Neuropathy among Breast Cancer Patients-A Randomized Controlled Study.
    Abouelmagd GMT; El-Karadawy SA; Abo-Ollo MM; Elwany YN; Mohamed ER; El-Amrawy WZ
    Pain Physician; 2023 Sep; 26(5):E497-E507. PubMed ID: 37774185
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of Wen-Luo-Tong on Peripheral Neuropathy Induced by Chemotherapy or Target Therapy: A Randomized, Double-Blinded, Placebo-Controlled Trial.
    Deng B; Jia LQ; Wan DG; Wang BY; Cheng ZQ; Deng C
    Chin J Integr Med; 2022 Jul; 28(7):579-585. PubMed ID: 35583581
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Patients With Colorectal Cancer: A Pilot Study.
    Chien A; Yang CC; Chang SC; Jan YM; Yang CH; Hsieh YL
    PM R; 2021 Jan; 13(1):55-65. PubMed ID: 32168417
    [TBL] [Abstract][Full Text] [Related]  

  • 68. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
    Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
    Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
    Kang L; Tian Y; Xu S; Chen H
    J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
    Gui Q; Li D; Zhuge Y; Xu C
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):705-709. PubMed ID: 33773532
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
    Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
    Fukushima J Med Sci; 2022 Apr; 68(1):1-10. PubMed ID: 35197393
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
    Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
    Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
    Matsuoka H; Ishiki H; Iwase S; Koyama A; Kawaguchi T; Kizawa Y; Morita T; Matsuda Y; Miyaji T; Ariyoshi K; Yamaguchi T
    BMJ Open; 2017 Aug; 7(8):e017280. PubMed ID: 28851798
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
    Yildirim N; Cengiz M
    Support Care Cancer; 2020 Oct; 28(10):4781-4788. PubMed ID: 31974772
    [TBL] [Abstract][Full Text] [Related]  

  • 75. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
    Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial.
    de Andrade DC; Jacobsen Teixeira M; Galhardoni R; Ferreira KSL; Braz Mileno P; Scisci N; Zandonai A; Teixeira WGJ; Saragiotto DF; Silva V; Raicher I; Cury RG; Macarenco R; Otto Heise C; Wilson Iervolino Brotto M; Andrade de Mello A; Zini Megale M; Henrique Curti Dourado L; Mendes Bahia L; Lilian Rodrigues A; Parravano D; Tizue Fukushima J; Lefaucheur JP; Bouhassira D; Sobroza E; Riechelmann RP; Hoff PM; ; Valério da Silva F; Chile T; Dale CS; Nebuloni D; Senna L; Brentani H; Pagano RL; de Souza ÂM
    Oncologist; 2017 Oct; 22(10):1154-e105. PubMed ID: 28652279
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized, double-blinded, placebo-controlled clinical trial of duloxetine hydrochloride enteric-coated tablets in the treatment of refractory chronic cough.
    Wang S; Li S; Wu H; Zhang T; Chen Y; Zhu Y; Wen S; Shi C; Yu L; Xu X
    BMC Pulm Med; 2023 Aug; 23(1):282. PubMed ID: 37533019
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study.
    Yokoyama S; Nakagawa C; Hosomi K
    Support Care Cancer; 2022 Feb; 30(2):1765-1773. PubMed ID: 34595605
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.
    Zirpoli GR; McCann SE; Sucheston-Campbell LE; Hershman DL; Ciupak G; Davis W; Unger JM; Moore HCF; Stewart JA; Isaacs C; Hobday TJ; Salim M; Hortobagyi GN; Gralow JR; Budd GT; Albain KS; Ambrosone CB
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29546345
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
    Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
    Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.